CABALETTA BIO INC. - COMMON STOCK

Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024

18 Nov 2024 06:00:00 By Nasdaq GlobeNewswire

Cabaletta Bio Reports Third Quarter 2024 Financial Results and Provides Business Update

14 Nov 2024 06:00:00 By Nasdaq GlobeNewswire

Cabaletta Bio to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference

06 Nov 2024 07:00:00 By Nasdaq GlobeNewswire

Cabaletta Bio to Present New and Updated Clinical Data on CABA-201 in Oral and Poster Presentations at ACR Convergence 2024

25 Sep 2024 15:30:00 By Nasdaq GlobeNewswire

Cabaletta Bio to Participate in Upcoming Investor Conferences in September

28 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Cabaletta Bio Reports Second Quarter 2024 Financial Results and Provides Business Update

08 Aug 2024 06:00:00 By Nasdaq GlobeNewswire

Cabaletta Bio to Participate in the Stifel 2024 Virtual Cell Therapy Forum

02 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

Cabaletta Bio Reports Positive Initial Clinical Data from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Trials of CABA-201

14 Jun 2024 01:00:00 By Nasdaq GlobeNewswire

Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference

29 May 2024 07:00:00 By Nasdaq GlobeNewswire

Cabaletta Bio Reports First Quarter 2024 Financial Results and Provides Business Update

15 May 2024 06:00:00 By Nasdaq GlobeNewswire

Cabaletta Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ

13 May 2024 07:00:00 By Nasdaq GlobeNewswire

Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

21 Mar 2024 06:00:00 By Nasdaq GlobeNewswire

Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis

20 Mar 2024 06:00:00 By Nasdaq GlobeNewswire

Cabaletta Bio to Participate in Upcoming Investor Conferences in March

27 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis

01 Feb 2024 15:30:00 By Nasdaq GlobeNewswire

Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

31 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Cabaletta Bio Receives Additional FDA Fast Track Designations for CABA-201 in Dermatomyositis and Systemic Sclerosis

08 Jan 2024 06:00:00 By Nasdaq GlobeNewswire

Cabaletta Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference

02 Jan 2024 07:00:00 By Nasdaq GlobeNewswire

Cabaletta Bio to Participate in the 6th Annual Evercore ISI HealthCONx Conference

28 Nov 2023 15:30:00 By Nasdaq GlobeNewswire

Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update

09 Nov 2023 06:00:01 By Nasdaq GlobeNewswire